Related Experiment Video
Updated: Jan 22, 2026

External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI
Sang Min Lee1, Jeong Min Lee1, Su Joa Ahn1
1From the Department of Radiology, Hallym University Sacred Heart Hospital, Gyeonggi-do, Republic of Korea (S.M.L.); Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea (J.M.L., S.J.A., H.J.K., H.K.Y., J.H.Y.); Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea (J.M.L., J.H.Y.); Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea (J.M.L.); and Department of Medical Imaging, Saint Michael's Hospital, University of Toronto, Toronto, ON, Canada (H.K.Y.).
Abstract:
Background Few studies have reported on the diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) LR-5 or LR-5 V in the diagnosis of hepatocellular carcinoma (HCC) using MRI with gadoxetate disodium. Purpose To determine the diagnostic performance of LI-RADS version 2018 (hereafter, v2018) on gadoxetate disodium-enhanced MRI in comparison with LI-RADS version 2017 (hereafter, v2017) for the diagnosis of HCC in patients with cirrhosis or chronic hepatitis B viral infection or at high risk for HCC. Materials and Methods This retrospective study between January 2013 and October 2015 evaluated consecutive patients at high risk for HCC who had at least one observation of 10 mm or greater on gadoxetate disodium-enhanced MRI and no history of previous treatment for hepatic lesions. MRI features were reviewed by three radiologists. Observations were categorized according to LI-RADS v2018 and LI-RADS v2017. Per-observation sensitivity and specificity of LR-5 using LI-RADS v2017 and v2018 were compared using generalized estimating equation models. Results A total of 422 observations, including 234 HCCs confirmed by results of pathologic examination in 387 patients (305 men and 82 women; mean age ± standard deviation, 59 years ± 10), were included. In all observations, LI-RADS v2018 provided higher sensitivity than LI-RADS v2017 (81% [189 of 234] vs 68% [160 of 234], respectively; P < .001). In small observations (10-19 mm), LI-RADS v2018 yielded much higher sensitivity than LI-RADS v2017 (76% [34 of 45] vs 11% [five of 45], respectively; P < .001) with relatively little impairment of specificity (94% [121 of 128] vs 99% [127 of 128], respectively; P = .013). Conclusion Updated LR-5 criteria of Liver Imaging Reporting and Data System (LI-RADS) version 2018 on gadoxetate disodium-enhanced MRI can improve sensitivity in the diagnosis of small hepatocellular carcinomas (10-19 mm) with only slight impairment in specificity compared with the criteria of LI-RADS version 2017. © RSNA, 2019 Online supplemental material is available for this article.
Related Concept Videos
Self-Evaluation: Self-Enhancement and Self-Verification
Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
Formulating and Validating Nursing Diagnosis I
There are thirteen domains...
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement

